All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-08-23T12:42:46.000Z

How might olutasidenib long-term data impact treatment strategies in patients with IDH1-mutated R/R AML?

Featured
Aug 23, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in AML.

During the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, the AML Hub was pleased to speak with Jorge Cortes, Augusta University, Augusta, US. We asked, How might long-term follow-up data regarding olutasidenib impact treatment strategies in patients with IDH1-mutated relapsed/refractory (R/R) acute myeloid leukemia (AML)? 

How might olutasidenib long-term data impact treatment strategies in patients with IDH1-mu R/R AML?

In December 2022, olutasidenib was granted  U.S. Food and Drug Administration (FDA) approval for the treatment of patients with IDH1-mutated R/R AML. Here, Cortes discusses the final 5-year efficacy and safety findings from the pivotal cohort of the phase II trial (NCT02719574) of olutasidenib in patients with IDH1-mutated R/R AML. Cortes highlights the high complete remission (CR)/CR with partial hematological recovery rate (35%), overall response rate (48%) and durable remission rates, as well as the prolonged survival and minimal toxicity of olutasidenib in patients with IDH1-mutated R/R AML including in patients who are R/R to prior venetoclax therapy. He mentions that olutasidenib is a promising treatment option for patients with R/R AML with IDH1 mutations; however, its comparison with other treatments, such as ivosidenibwhich is also highly effective and commercially availableremains uncertain without a randomized trial. 

Your opinion matters

HCPs, what is your preferred format for educational content on the AML Hub?
7 votes - 36 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox